Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial (vol 321, pg 1445, 2000)

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial (vol 321, pg 1445, 2000)

Opis bibliograficzny
1. autor:	Wilcock, G
Format:	Journal article
Wydane:	2001

Podobne zapisy

Erratum: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial (British Medical Journal (December 9) (1445-1449))
od: Wilcock, G
Wydane: (2001)

Erratum: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial (British Medical Journal (December 9)(1445-1449))
od: Wilcock, G
Wydane: (2001)

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group.
od: Wilcock, G, i wsp.
Wydane: (2000)

Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial.
od: Pirttilä, T, i wsp.
Wydane: (2004)

Galantamine in Alzheimer's disease.
od: Razay, G, i wsp.
Wydane: (2008)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
od: Ben Seltzer
Wydane: (2009-12-01)

Safety and efficacy of galantamine in subjects with mild cognitive impairment.
od: Winblad, B, i wsp.
Wydane: (2008)

The beneficial effects of galantamine on caregiver time in Alzheimer's disease
od: Sano, M, i wsp.
Wydane: (2003)

The effects of galantamine treatment on caregiver time in Alzheimer's disease.
od: Sano, M, i wsp.
Wydane: (2003)

A long-term comparison of galantamine and donepezil in the treatment of moderate-to-severe Alzheimer's disease: An intent-to-treat analysis
od: Wilcock, G, i wsp.
Wydane: (2003)

Loss of perineuronal net N-acetylgalactosamine in Alzheimer's disease (vol 110, pg 393, 2005)
od: Baig, S, i wsp.
Wydane: (2006)

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
od: Wilcock, G, i wsp.
Wydane: (2008)

A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease.
od: Wilcock, G, i wsp.
Wydane: (2003)

Visual mismatch negativity highlights abnormal pre-attentive visual processing in mild cognitive impairment and Alzheimer's disease (vol 5, pg 1224, 2008)
od: Tales, A, i wsp.
Wydane: (2010)

Long-term efficacy and safety of galantamine in outpatients with mild cognitive disorder
od: Schmidt Luisa, i wsp.
Wydane: (2010-04-01)

Galantamine vs donepezil in the treatment of Alzheimer's disease.
od: Goldlist, B, i wsp.
Wydane: (2003)

Three-year follow-up of galantamine therapy for Alzheimer's disease: Efficacy and tolerability in open-label extension studies
od: Wilcock, G, i wsp.
Wydane: (2002)

Galantamine plasma concentration and cognitive response in Alzheimer’s disease
od: Yi-Ting Lin, i wsp.
Wydane: (2019-05-01)

Alzheimer's disease, herpes virus in the brain, apolipoprotein E4 and herpes labialis. (vol 1, pg 173, 1998)
od: Lin, W, i wsp.
Wydane: (1998)

Effect of galantamine on time to residential or nursing home admission
od: Feldman, H, i wsp.
Wydane: (2004)

TNFR-associated factor-2 (TRAF-2) in Alzheimer's disease (vol 30, pg 1052, 2009)
od: Culpan, D, i wsp.
Wydane: (2010)

Sandro Botticelli (1445-1510)
Wydane: (2023-03-01)

Can we predict the response to Galantamine in Alzheimer`s disease patients?
od: Carmen Gavan, i wsp.
Wydane: (2015-09-01)

The zeta function of sl(2)(Z) (vol 12, pg 197, 2000)
od: du Sautoy, M
Wydane: (2000)

Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
od: Brian Lawlor, i wsp.
Wydane: (2018-09-01)

Design and development of galantamine hydrobromide transdermal patch for treatment of alzheimer’s disease
od: Woo, Fong Yen
Wydane: (2015)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
od: Yasir Hasan Siddique, i wsp.
Wydane: (2022-01-01)

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease
od: E Loveman, i wsp.
Wydane: (2006-01-01)

Long-term safety, tolerability and efficacy of galantamine: Results from a 36-month analysis of extension study data
od: Wilcock, G, i wsp.
Wydane: (2002)

A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).
od: Wilcock, G, i wsp.
Wydane: (2002)

Patterns of clinically detectable treatment effects with galantamine: a qualitative analysis.
od: Joffres, C, i wsp.
Wydane: (2003)

Moderate Hypothermia to Treat Perinatal Asphyxial Encephalopathy (vol 361, pg 1349, 2009)
od: Azzopardi, D, i wsp.
Wydane: (2010)

Hierarchical adhesive hydrogel microparticles with galantamine hydrobromide encapsulation for the treatment of Alzheimer’s disease
od: Huijuan Zhou, i wsp.
Wydane: (2024-10-01)

Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials.
od: Whitehead, A, i wsp.
Wydane: (2004)

Galantamine ameliorates experimental pancreatitis
od: Dane A. Thompson, i wsp.
Wydane: (2023-10-01)

Mechanistic insights into MARK4 inhibition by galantamine toward therapeutic targeting of Alzheimer’s disease
od: Mohd Adnan, i wsp.
Wydane: (2023-09-01)

La carta puebla de Señera en 1445
od: Primitivo J. Pla Alberola
Wydane: (1993-12-01)

Carried meningococci in the Czech Republic: a diverse recombining population (vol 38, pg 4492, 2000)
od: Jolley, K, i wsp.
Wydane: (2002)

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
od: Dan-Dan Li, i wsp.
Wydane: (2019-05-01)

In the beginning (vol 158, pg 7, 1998)
od: Sarkar, S, i wsp.
Wydane: (1998)